Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
TRELSTAR (triptorelin pamoate) is a GnRH agonist administered as an intramuscular injection for the treatment of advanced prostate cancer and other hormone-responsive conditions. It works by desensitizing pituitary GnRH receptors, leading to suppression of luteinizing hormone and follicle-stimulating hormone, thereby reducing testosterone production.
As LOE approaches, the brand team is likely consolidating and transitioning from growth-focused to defense and lifecycle extension strategies; career growth may be limited unless repositioning to adjacent indications occurs.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
Worked on TRELSTAR at Verity Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TRELSTAR offers limited career growth opportunity as the product approaches loss of exclusivity with zero currently linked positions. Working on this product is suitable for professionals seeking stable, specialized expertise in oncology commercials or market access, but advancement requires lateral mobility into pipeline or growth-stage franchises.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo